top of page

Akthelia has a portfolio of small molecule candidate therapeutics in development, with a lead program in chemotherapy-induced febrile neutropenia/neutropenic sepsis, the leading cause of treatment-related mortality affecting cancer chemotherapy patients.


Our pre-clinical stage asset portfolio 

Our exciting pre-clinical stage portfolio includes our lead program - an oral prophylactic treatment for chemically induced febrile neutropenia designed to prevent life threatening infections that occur in immunocompromised patients undergoing cancer chemotherapy. 

Akthelia Asset Pipeline.jpg
bottom of page